Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Risankizumab in moderately to severely active Crohn's disease
NCT02031276Phase 2Completed
- Sponsor
- AbbVie Inc.
- Start
- Feb 2014
- Primary completion
- Dec 2015
- Modality
- Monoclonal Antibodies
01
Overview
A Phase 2 trial of risankizumab in Crohn's disease, sponsored by AbbVie Inc.. Started Feb 2014; status: completed.
02
Drugs
risankizumab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT02031276.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02031276.